Doctor's Bio
A board-certified medical oncologist, Dr. Jennifer W. Carlisle, MD, specializes in the care of patients with lung cancer, mesothelioma, and thymic malignancies.
Dr. Carlisle’s research interests include translational studies that advance the understanding of immunobiology and immunotherapies. In 2018, she was selected to participate in the ASCO/AACR Methods in Clinical Cancer Research Workshop in Vail. By designing and performing thoughtful and innovative clinical trials with immune correlates, she aims to contribute to the development of new regimens and novel combinations that improve outcomes for patients.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: University of Florida
- Residency: Washington University School of Medicine
Fellowships
Emory University School of Medicine
Locations and Directions
Correll Pavilion
Phone: (404) 616-1000
Location:
80 Gilmer St. SE
Atlanta, GA 30303
Publications
- Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.
Carlisle JW, O'Reilly K, Ji XA, Switchenko JM, Steuer CE, Ardeshir-Larijani F, Ramalingam SS, Leal T
JCO oncology practice. 2026;
PMID: 42418753 - HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.
Carlisle JW, Woods SD, Badgett R, Alvarez P, Anziska Y
Journal of the National Comprehensive Cancer Network : JNCCN. 2026;
PMID: 41990809 - Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion.
Medina CB, Sobierajska E, Gong M, McManus DT, Thapa M, Lee J, Im SJ, Toombs JE, Mitchell JM, Wang Y, Carlisle JW, Freeman GJ, Master VA, Ramalingam SS, Kissick HT, Li S, Brekken RA, Ahmed R
Nature. 2026;653(8115):879-887.
PMID: 41882354 - Survival Determinants and Sociodemographic Disparities in Early-Onset Non-Small Cell Lung Cancer.
Kar I, Vhora F, Bou Zerdan M, Canaslan K, Balaji D, El Osta B, Balaji S, O'Reilly K, Leal T, Jain T, Ramalingam S, Steuer CE, Carlisle JW, Bozkurt S, Ardeshir-Larijani F
JAMA network open. 2025;8(10):e2537307.
PMID: 41082228 - Setting Expectations: Using Real-World Data to Guide Patients on Frontline Osimertinib.
Carlisle JW, Leal T
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025;20(9):1161-1163.
PMID: 40914596 - Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.
Aijaz A, Pannu S, Abushukair H, Mitchell CL, Hsu ML, Johnson ML, Carlisle JW, Naqash AR
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025;45(3):e472794.
PMID: 40440602 - Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.
Carlisle JW, Wolner Z, Pannu S, Mitchell C, Hsu M, Aijaz A, Johnson M, Naqash AR
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025;45(3):e472792.
PMID: 40397846 - Safety and Tolerability of Lete-cel in NSCLC-Reply.
Altan M, Lopes G, Hiltermann TJN, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O'Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ
Clinical cancer research : an official journal of the American Association for Cancer Research. 2025;31(9):1810-1811.
PMID: 40308090 - A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".
Carlisle JW, Pentz RD, Ramalingam SS
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025;20(4):e53.
PMID: 40204397 - Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK
Cancer. 2025;131(3):e35738.
PMID: 39876075
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.